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DNA methylation alteration, in correlation with gene expression, is involved 
in develop-ment and progression of many cancers. Using a microarray based 
method, mouse-DMH (Differential Methylation Hybridization), our lab is able 
to study DNA methylation changes during prostate cancer progression in the 
TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mouse model. Currently, 
there are about 3000 CpG islands on the microarray, which were used as probes 
to detect DNA methylation changes.  
 
In order to improve our ability to screen for a larger number of CpG island 
methylation changes, we are working on adding about 2000 more mouse CpG 
islands onto the array. In addition, we have successfully designed primers 
and PCR amplified CpG islands for tumor suppressor genes and proto-oncogenes 
which have been previously reported in literature to be differentially 
methylated during development of human prostate cancer. These genes include 
AR (Androgen Receptor), ERα (Estrogen Receptor alpha), ERβ(Estrogen Receptor 
beta) and GSTP1 (Glutathione S-Transferase PI). Primer design and PCR 
amplification for other known tumor suppressors/oncogenes is still in 
process. 
 
The microarray-based mouse-DMH is a tool of great potential. It can easily be 
adapted to screen for DNA methylation changes in other mouse cancer models 
and generate valu-able data leading to understanding of the molecular 
mechanism behind cancer development, which will in turn contribute to 
treatment of human cancers. 
 
